Literature DB >> 19554569

Deep brain stimulation effects on gait variability in Parkinson's disease.

Jeffrey M Hausdorff1, Leor Gruendlinger, Lisa Scollins, Siobhan O'Herron, Daniel Tarsy.   

Abstract

The effects of subthalamic nucleus (STN) deep brain stimulation (DBS) on fall risk in patients with Parkinson's disease (PD) currently remain unclear. Although several gait parameters, such as gait speed, have shown improvement with DBS, some studies have reported an increased fall risk following DBS. The purpose of this study was to examine the effect of bilateral DBS on gait variability, a marker of fall risk. The gait of 13 patients with idiopathic PD was analyzed to determine the influence of DBS, levodopa and both therapies together. Following treatment with both levodopa and STN DBS, subjects displayed improved gait speed, reduced gait variability (enhanced stability), and lower Unified Parkinson's Disease Rating Scale (UPDRS) scores. Although UPDRS scores improved with STN DBS alone, parallel improvements were not seen for gait variability. These findings suggest that different mechanisms may contribute to performance on UPDRS motor testing and gait stability in response to DBS. 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19554569     DOI: 10.1002/mds.22554

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD.

Authors:  R J St George; J G Nutt; K J Burchiel; F B Horak
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

Review 2.  Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments.

Authors:  Philipp Mahlknecht; Patricia Limousin; Thomas Foltynie
Journal:  J Neurol       Date:  2015-06-03       Impact factor: 4.849

Review 3.  The effect of STN DBS on modulating brain oscillations: consequences for motor and cognitive behavior.

Authors:  Fabian J David; Miranda J Munoz; Daniel M Corcos
Journal:  Exp Brain Res       Date:  2020-06-03       Impact factor: 1.972

Review 4.  Freezing of gait in Parkinson's disease: where are we now?

Authors:  Elke Heremans; Alice Nieuwboer; Sarah Vercruysse
Journal:  Curr Neurol Neurosci Rep       Date:  2013-06       Impact factor: 5.081

5.  Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease.

Authors:  Narayanan Krishnamurthi; Holly Shill; Darolyn O'Donnell; Padma Mahant; Johan Samanta; Abraham Lieberman; James Abbas
Journal:  Arch Phys Med Rehabil       Date:  2016-10-27       Impact factor: 3.966

Review 6.  Framework for understanding balance dysfunction in Parkinson's disease.

Authors:  Bernadette Schoneburg; Martina Mancini; Fay Horak; John G Nutt
Journal:  Mov Disord       Date:  2013-08-07       Impact factor: 10.338

Review 7.  The brain map of gait variability in aging, cognitive impairment and dementia-A systematic review.

Authors:  Qu Tian; Nathalie Chastan; Woei-Nan Bair; Susan M Resnick; Luigi Ferrucci; Stephanie A Studenski
Journal:  Neurosci Biobehav Rev       Date:  2017-01-20       Impact factor: 8.989

8.  Effects of deep brain stimulation in the subthalamic nucleus or globus pallidus internus on step initiation in Parkinson disease: laboratory investigation.

Authors:  Laura Rocchi; Patricia Carlson-Kuhta; Lorenzo Chiari; Kim J Burchiel; Penelope Hogarth; Fay B Horak
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

9.  Medication and subthalamic nucleus deep brain stimulation similarly improve balance and complex gait in Parkinson disease.

Authors:  Marie E McNeely; Gammon M Earhart
Journal:  Parkinsonism Relat Disord       Date:  2012-08-10       Impact factor: 4.891

Review 10.  Deep brain stimulation improves gait velocity in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Jaimie A Roper; Nyeonju Kang; Juliana Ben; James H Cauraugh; Michael S Okun; Chris J Hass
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.